New anticoagulant therapy.

Jeffrey I Weitz, Lori-Ann Linkins

Journal: Annual review of medicine 2005;56():63-77

PMID: 15660502

Abstract

The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined therapy than vitamin K antagonists. This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants.

Address: McMaster University and Henderson Research Center, Hamilton, Ontario, Canada L8V 1C3. [email protected]

DOI: 10.1146/annurev.med.56.082103.104708

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://www.annualreviews.org/content/journals/10....

MeSH Terms: Administration, Oral, Anticoagulants, Antithrombin III, Clinical Trials as Topic, Drugs, Investigational, Factor VIIIa, Factor VIIa, Factor Va, Humans, Lipoproteins, Thrombin, Thrombosis